ViroCell Biologics requests that their press release NewsItemId: 20231211079092 issued December 12, 2023 “ViroCell Signs Manufacturing Services Agreement with UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer” be killed.
The release was issued prematurely by ViroCell Biologics.
Contacts
For more company information, please contact:
ViroCell
John W. Hadden II, CEO
info@virocell.com
For media enquiries, please contact:
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Tim Stamper
ViroCell@fticonsulting.com
+44 (0)20 3727 1000
